---
layout: post
title: "新冠检测概念爆发 这家公司一季度日赚1.5亿 股价三连板 还有这些公司业绩大增"
date: 2022-04-14 19:57:49 +0800
categories: emnews
tags: 东财滚动新闻
---
> 疫情反复，新冠检测需求旺盛，多家公司一季度业绩大增。今日上证指数震荡拉升，收盘上涨1.22%，深证成指、科创板指均涨逾1%，创业板指微跌。盘面上，新冠检测板块再度爆发，概念指数收盘大涨4.31%，板块内兰卫医学、泰林生物20%涨停，万孚生物涨近15%，热景生物涨11%。一季度日赚超1.5亿元的九安医疗业绩预告发布后收获三连板，今日发布业绩预增公告的明德生物高开后迅速涨停。（证券时报）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002432" data-code="002432|0|2" data-code2="002432|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002432&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002432_0" data-code="K 002432|0|2" data-code2="K 002432|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1062" data-code="BK1062|90|1" data-code2="BK1062|90|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1062&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1062_0" data-code="K BK1062|90|1" data-code2="K BK1062|90|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>疫情反复，新冠检测需求旺盛，多家公司一季度<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>大增。<br /></p><p>今日<span id="Info.3258"><a href="http://quote.eastmoney.com/unify/r/1.000001" class="infokey">上证指数</a></span>震荡拉升，收盘上涨1.22%，<span id="Info.3260"><a href="http://quote.eastmoney.com/unify/r/0.399001" class="infokey">深证成指</a></span>、科创板指均涨逾1%，<span id="Info.3259"><a href="http://quote.eastmoney.com/unify/r/0.399006" class="infokey">创业板指</a></span>微跌。盘面上，新冠检测板块再度爆发，概念指数收盘大涨4.31%，板块内<strong><span id="stock_0.301060"><a href="http://quote.eastmoney.com/unify/r/0.301060" class="keytip" data-code="0,301060">兰卫医学</a></span><span id="quote_0.301060"></span>、<span id="stock_0.300813"><a href="http://quote.eastmoney.com/unify/r/0.300813" class="keytip" data-code="0,300813">泰林生物</a></span><span id="quote_0.300813"></span></strong>20%涨停，<strong><span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span></strong>涨近15%，<strong><span id="stock_1.688068"><a href="http://quote.eastmoney.com/unify/r/1.688068" class="keytip" data-code="1,688068">热景生物</a></span><span id="quote_1.688068"></span></strong>涨11%。一季度日赚超1.5亿元的<strong><span id="stock_0.002432"><a href="http://quote.eastmoney.com/unify/r/0.002432" class="keytip" data-code="0,002432">九安医疗</a></span><span id="quote_0.002432"></span></strong>业绩预告发布后收获三连板，今日发布业绩预增<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>的<strong><span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span></strong>高开后迅速涨停。</p><p><strong>新冠检测需求旺盛</strong></p><p><strong>多家公司首季业绩大增</strong></p><p>国内外疫情反复，国内新冠检测相关公司在抗疫过程中发挥重要作用。</p><p><span id="stock_1.601901"><a href="http://quote.eastmoney.com/unify/r/1.601901" class="keytip" data-code="1,601901">方正证券</a></span><span id="quote_1.601901"></span>3月20日<span id="Info.3319"><a href="http://data.eastmoney.com/report/" class="infokey">研报</a></span>表示，随着病毒传播力增强，新冠防控相关需求提升，检测服务龙头企业因品牌和规模效应业绩有望大超预期；核酸检测试剂产品规模化成本优势及渠道逐步稳固，抗原自检海外需求趋于稳定，国内需求关注防控政策调整或核酸筛查能力瓶颈的地区。</p><p>新冠防控需求提升，对板块内不少公司业绩有明显的推动作用。<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>时报·数据宝统计，截至4月14日多家新冠检测概念公司发布一季度业绩预告，盈利最多的是<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.002432" class="em_stock_key_common" data-code="0,002432">九安医疗</span></strong>，公司一季度预计盈利140亿元至160亿元，同比增长367倍~420倍。因受美国疫情发展的影响，当地对新冠抗原检测试剂盒产品需求大幅增长，该产品的销售收入增长为公司报告期内的业绩作出重要贡献。业绩预告发布后股价连续三天涨停，对于股价异常波动，公司也进行风险提示：未来美国疫情发展的不确定性及市场竞争形势的改变，对公司产品的需求及市场份额和产品价格都将产生影响。</p><p>今日发布业绩预告的<strong><span web="1" href="http://quote.eastmoney.com/unify/r/0.002932" class="em_stock_key_common" data-code="0,002932">明德生物</span></strong>，预计一季度盈利13.5亿元至14.5亿元，同比增长296%~325%。主因各地为防控疫情加大核酸检测频率，增加对新冠核酸检测试剂的需求，公司新冠核酸检测试剂及服务等相关收入大幅增长，多地疫情反复促使公司新冠抗原检测试剂盒出口订单同比大幅增长。</p><p><strong><span id="stock_1.688606"><a href="http://quote.eastmoney.com/unify/r/1.688606" class="keytip" data-code="1,688606">奥泰生物</a></span><span id="quote_1.688606"></span></strong>新冠检测业务订单继续保持稳定增长，预计一季度盈利10.3亿元至11.9亿元，同比增585%~692%。从<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>同比增幅下限看，除上述几家公司，<strong><span id="stock_0.300639"><a href="http://quote.eastmoney.com/unify/r/0.300639" class="keytip" data-code="0,300639">凯普生物</a></span><span id="quote_0.300639"></span>、<span id="stock_0.300485"><a href="http://quote.eastmoney.com/unify/r/0.300485" class="keytip" data-code="0,300485">赛升药业</a></span><span id="quote_0.300485"></span></strong>等首季净利润同比均翻倍。</p><p><strong>6股<span id="Info.3291"><a href="http://data.eastmoney.com/zlsj/" class="infokey">主力</a></span>资金抢筹超亿元</strong></p><p>新冠检测板块活跃，部分个股获主力资金青睐，数据宝统计，<strong><span id="stock_0.000710"><a href="http://quote.eastmoney.com/unify/r/0.000710" class="keytip" data-code="0,000710">贝瑞基因</a></span><span id="quote_0.000710"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300482" class="em_stock_key_common" data-code="0,300482">万孚生物</span>、<span id="stock_0.002584"><a href="http://quote.eastmoney.com/unify/r/0.002584" class="keytip" data-code="0,002584">西陇科学</a></span><span id="quote_0.002584"></span>、<span id="stock_0.002030"><a href="http://quote.eastmoney.com/unify/r/0.002030" class="keytip" data-code="0,002030">达安基因</a></span><span id="quote_0.002030"></span></strong>等6股获主力资金<span id="Info.313"><a href="http://data.eastmoney.com/zjlx/" class="infokey">净流入</a></span>超亿元。</p><p><span id="Info.327"><a href="http://data.eastmoney.com/rzrq/sh.html" class="infokey">融资融券</a></span>方面，截至4月13日，有8股近10日获杠杆资金加仓5%以上，期间融资余额增幅居前的有<strong><span id="stock_0.301235"><a href="http://quote.eastmoney.com/unify/r/0.301235" class="keytip" data-code="0,301235">华康医疗</a></span><span id="quote_0.301235"></span>、<span id="stock_1.688075"><a href="http://quote.eastmoney.com/unify/r/1.688075" class="keytip" data-code="1,688075">安旭生物</a></span><span id="quote_1.688075"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688606" class="em_stock_key_common" data-code="1,688606">奥泰生物</span></strong>等，分别增长61.36%、19.09%、17.69%。期间北向资金加仓的有16只，加仓幅度较大的是<strong><span id="stock_0.002589"><a href="http://quote.eastmoney.com/unify/r/0.002589" class="keytip" data-code="0,002589">瑞康医药</a></span><span id="quote_0.002589"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300639" class="em_stock_key_common" data-code="0,300639">凯普生物</span>、<span id="stock_0.002643"><a href="http://quote.eastmoney.com/unify/r/0.002643" class="keytip" data-code="0,002643">万润股份</a></span><span id="quote_0.002643"></span></strong>，增仓幅度为82.15%、59.51%、34.80%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25195569586095676439_w951h699.jpg" alt="Image" width="100%" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>时报）</p>

<http://finance.eastmoney.com/news/1354,202204142343768583.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)